Evidence map›Paper›PMID 24000378›Full record

ArticleClinical trials (London, England)2013

How good does the science have to be in proposals submitted to Institutional Review Boards? An interview study of Institutional Review Board personnel.

Robert Klitzman

Abstract read
In one paragraph

Article in Clinical trials (London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. A Scoping Review of Empirical Research on Research Ethics Board Membership and Expertise.Journal of empirical research on human research ethics : JERHRE · 2025
    Article
  2. Article
  3. A Qualitative Study on Experiences and Perspectives of Members of a Dutch Medical Research Ethics Committee.HEC forum : an interdisciplinary journal on hospitals' ethical and legal issues · 2020
    Article
  4. Article
  5. Article
  6. Deciding how many embryos to transfer: ongoing challenges and dilemmas.Reproductive biomedicine & society online · 2016
    Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Robert KlitzmanMasters of Bioethics Program, Columbia University, New York, USA.

Funding

The Statistics, Data Science, and Data Management (SDM) CoreP30MH043520 · NIMH · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI MILTON L WAINBERG · 2003 to 2026
$48.2M
Views and Approaches Toward Research Integrity Among IRBsR01HG004214 · NHGRI · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI KLITZMAN, ROBERT L · 2006 to 2007
$567k
IRBs: Ethics, Context and InterpretationsG13LM009996 · NLM · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI KLITZMAN, ROBERT L · 2009 to 2011
$240k
NHGRI NIH HHS R01 HG004214NIMH NIH HHS P30 MH043520NLM NIH HHS 5-G13-LM009996-02NLM NIH HHS G13 LM009996PHS HHS R01-NG04214
6 · The paper itself

Abstract

backgroundInstitutional Review Boards (IRBs) have been increasingly criticized for how they review protocols, but how IRBs perceive, and make decisions about, the quality of the science of protocols has not been examined. PURPOSE: To explore how and when IRBs view and make decisions about the quality of the science of studies they review.

methodsI contacted the leadership of 60 IRBs (every fourth one in the list of the top 240 institutions by National Institutes of Health (NIH) funding) and interviewed IRB chairs, co-chairs, administrators, and a director from 34 IRBs (response rate = 55%), and an additional 7 members.

resultsInterviewees faced several ambiguities and questions concerning the quality of the science of protocols. IRBs are often not sure how and to what extent to evaluate the science of protocols, whether the science should be 'good enough' (and if so, what that means) versus as good as possible. Federal regulations state that IRBs should ensure that risks are minimized, and commensurate with benefits. Thus, at times IRBs feel that changing the science is ethically necessary. But IRBs also then struggle with whether to adopt a higher threshold (1) that social and thus scientific benefits be maximized and (2) that scientific efforts and resources should not be wasted. Committees face dilemmas - for example, if a 'perfect' study is not feasible. For protocols already approved elsewhere (e.g., by the NIH), IRBs vary in how much they feel they can request alterations, and sometimes make changes nonetheless. Larger institutional contexts and biases can shape these issues, and IRBs differ in how much they are 'pro-research', and have sufficient expertise. IRBs at times also approve studies despite reservations about the science. LIMITATIONS: This study includes interviews with IRBs, but not observations of IRB meetings.

conclusionsIRBs often face ambiguities and conflicting goals in assessing scientific quality. Many IRBs try to improve the science beyond what the regulations mandate. These data have important implications for improving practice, education, research, and policy.

Indexed as

Ethics Committees, ResearchClinical ProtocolsClinical Trials as TopicGoalsHumansInterviews as Topic

Identifiers

PMID24000378
PMCPMC3918462

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.